Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02368951
Other study ID # 16897
Secondary ID
Status Terminated
Phase Phase 1
First received February 16, 2015
Last updated July 10, 2017
Start date March 24, 2015
Est. completion date July 27, 2016

Study information

Verified date July 2017
Source Bayer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-FGFR2 antibody drug conjugate BAY1187982 in subjects with advanced solid tumors known to express fibroblast growth factor receptor 2 (FGFR2)


Recruitment information / eligibility

Status Terminated
Enrollment 20
Est. completion date July 27, 2016
Est. primary completion date July 27, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- All subjects must be >/= 18 years at the first screening examination / visit

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

- Subjects with advanced, histologically or cytologically confirmed solid tumors described to express fibroblast growth factor receptor 2 (FGFR2) that are refractory to any standard therapy

- For maximum tolerated dose (MTD) Dose Expansion: Subjects with advanced, histologically or cytologically confirmed triple-negative breast cancer who had undergone within 4 lines of systemic anti-cancer treatment and not eligible for standard therapy anymore.

- Subjects need to have evaluable disease (measurable or not measurable).

- Women of childbearing potential must have a negative pregnancy test performed within 7 days prior to the start of treatment

Exclusion Criteria:

- History of allergic reactions to monoclonal antibody therapy (or excipients in the formulation)

- Anti-cancer chemotherapy, experimental cancer therapy including clinical trial, or cancer immunotherapy within 4 weeks prior to the first dose of the investigational drug.

- Toxic effects of previous anti-cancer chemotherapy, experimental cancer therapy, or cancer immunotherapy have not normalized.

- History of symptomatic metastatic brain or meningeal tumors unless the subject is longer than 3 months from the end of definitive therapy before the first dose of the investigational drug and has clinically or radiologically no evidence of tumor growth.

- History of clinically significant cardiac disease

- Congenital coagulation abnormalities

- Subjects who are pregnant or are breast-feeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BAY1187982
A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the starting dose based on toxicology data. The investigational drug will be administered as a 1-hour IV infusion once every 21 days at the trial site (Day 1 of each 21-day Cycle). The maximum possible dose escalation will be 2-fold and not more than 0.5 mg/kg BW until maximum tolerated dose is selected

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Bayer

Countries where clinical trial is conducted

United States,  Korea, Republic of,  Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose(MTD) The MTD is defined as the maximum dose at which the incidence of DLTs during Cycle 1 is below 20%, or the maximum dose administered, whichever is achieved first during dose escalation Up to 2 years
Primary Number of subjects with adverse events as a measure of safety and tolerability Up to 2 years
Primary Number of subjects with serious adverse events as a measure of safety and tolerability Up to 2 years
Secondary Cmax (maximum observed drug concentration in measured matrix after single dose administration) Cycles 1 and 3, Day 1: pre-dose, end of infusion, Day 2, Day 3, Day 5, Day 8, and Day 15.Cycles 2 and 4: Day 1: pre-dose.Cycle 5 Day 1 and every odd cycles after: pre-dose and end of infusion
Secondary AUC(0-tlast) AUC from time 0 to the last data point >LLOQ Cycles 1 and 3, Day 1: pre-dose, end of infusion, Day 2, Day 3, Day 5, Day 8, and Day 15.Cycles 2 and 4: Day 1: pre-dose.Cycle 5 Day 1 and every odd cycles after: pre-dose and end of infusion
Secondary AUC)0-504 (AUC from zero to 504 hours post infusion) Cycles 1 and 3, Day 1: pre-dose, end of infusion, Day 2, Day 3, Day 5, Day 8, and Day 15.Cycles 2 and 4: Day 1: pre-dose.Cycle 5 Day 1 and every odd cycles after: pre-dose and end of infusion
Secondary AUC (area under the concentration vs. time curve from zero to infinity after single (first) Cycles 1 and 3, Day 1: pre-dose, end of infusion, Day 2, Day 3, Day 5, Day 8, and Day 15.Cycles 2 and 4: Day 1: pre-dose.Cycle 5 Day 1 and every odd cycles after: pre-dose and end of infusion
Secondary Cmax,md (maximum observed drug concentration in measured matrix after multiple dose administration during a dosage interval) Cycles 1 and 3, Day 1: pre-dose, end of infusion, Day 2, Day 3, Day 5, Day 8, and Day 15.Cycles 2 and 4: Day 1: pre-dose.Cycle 5 Day 1 and every odd cycles after: pre-dose and end of infusion
Secondary AUC(0-tlast)md (AUC from time 0 to the last data point >LLOQ after multiple dosing) Cycles 1 and 3, Day 1: pre-dose, end of infusion, Day 2, Day 3, Day 5, Day 8, and Day 15.Cycles 2 and 4: Day 1: pre-dose.Cycle 5 Day 1 and every odd cycles after: pre-dose and end of infusion
Secondary AUC(0-504)md Cycles 1 and 3, Day 1: pre-dose, end of infusion, Day 2, Day 3, Day 5, Day 8, and Day 15.Cycles 2 and 4: Day 1: pre-dose.Cycle 5 Day 1 and every odd cycles after: pre-dose and end of infusion
Secondary FGFR2 levels in tumor tissue sample Screening
Secondary CK18 levels in tumor tissue sample Screening, Cycles 1 and 3, Day 1: pre-dose, end of infusion, Day 2, Day 3, Day 5, Day 8, and Day 15.Cycles 2 and 4: Day 1: pre-dose and end of infusion.
Secondary Nucleosome level in plasma Screening, Cycles 1 and 3, Day 1: pre-dose, end of infusion, Day 2, Day 3, Day 5, Day 8, and Day 15.Cycles 2 and 4: Day 1: pre-dose and end of infusion.
Secondary Development of anti-drug antibodies (ADAs) in plasma as an indicator of immunogenicity Cycle 1: Day 1: before infusion (pre-dose), Day 8
Secondary Tumor response Screening, Day 15 (± 7 days) of Cycle 2 and every even subsequent Cycle (i.e. Cycles 2, 4, 6, 8, etc.)
See also
  Status Clinical Trial Phase
Completed NCT02824042 - Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Phase 1
Completed NCT02253420 - COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients Phase 1
Completed NCT02357953 - Transpulmonary Thermodilution Using an Implented Central Venous Access Port N/A
Completed NCT02645357 - Implementing an Evidence-based Computerized Decision Support System Linked to Electronic Health Records to Improve Care for Cancer Patients N/A
Recruiting NCT04931329 - Onco-haematology Vigilance Card
Terminated NCT02138812 - Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel Phase 1
Recruiting NCT05356182 - A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies N/A
Not yet recruiting NCT05423808 - Geriatric and Oncological Evaluation With Technology for Holistic Healthcare Management for Older Multimorbid Patients. N/A
Terminated NCT02439346 - Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel Phase 1
Recruiting NCT05385718 - Ezra Faster Scan Study
Completed NCT02457351 - Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study Phase 1
Completed NCT02906423 - Results From a Health System-wide Implementation of a Quality of Life Questionnaire N/A
Completed NCT01409135 - A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4 Phase 1
Not yet recruiting NCT02327806 - The Effect of Pullsed Magnetic Field Induction on Improving the Forearm Tissue Muscle Performance N/A
Completed NCT02639091 - Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors Phase 1
Completed NCT02366949 - Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel Phase 1
Not yet recruiting NCT06097533 - Improvement of Quality of Life by Cannabinoids in Oncologic Patients Phase 2/Phase 3
Completed NCT02427490 - A Problem-Solving Intervention for Family Caregivers in Palliative Oncology N/A
Recruiting NCT05359848 - A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy N/A